A Multicenter, Randomized, Double Blind Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderate to Severely Active Crohn's Disease

Grants and Contracts Details

StatusFinished
Effective start/end date7/7/17 → 4/15/22

Funding

  • AbbVie Incorporated: $108,910.00